Patent: 11,564,996
✉ Email this page to a colleague
Summary for Patent: 11,564,996
| Title: | Gene therapy for ocular disorders |
| Abstract: | Compositions and methods are provided for treating Leber congenital amaurosis (LCA) in a subject. In one aspect, a recombinant adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding Lebercilin. In another aspect, Lebercilin has an amino acid sequence of SEQ ID NO: 1. In yet another aspect, the nucleic acid molecule has a sequence of SEQ ID NO: 3 or a variant thereof. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate. |
| Inventor(s): | Jean Bennett, Jeannette BENNICELLI, Junwei Sun, Ji Yun Song, Sergei Nikonov |
| Assignee: | University of Pennsylvania Penn |
| Application Number: | US16/489,770 |
| Patent Claims: | see list of patent claims |
Details for Patent 11,564,996
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Spark Therapeutics, Inc. | LUXTURNA | voretigene neparvovec | Injection | 125610 | December 19, 2017 | ⤷ Start Trial | 2038-03-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 11,564,996
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2018160849 | ⤷ Start Trial |
| United States of America | 2023233709 | ⤷ Start Trial |
| United States of America | 2019388561 | ⤷ Start Trial |
| Russian Federation | 2019130004 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
